Yep, that is cutting it too fine for a 2000 persons clinical trial to get those Performance Shares. Do they just have to start the trial? Assay development for Bard1 Lung to commence Q4 2019.
Meanwhile, they are concentrating on commercialising Bard1 Ovarian/Breast. Clinical verification in Q3 2019.
From AGM Presentation 30 Nov 2018
Performance Shares, page-6
-
- There are more pages in this discussion • 26 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
58.5¢ |
Change
0.020(3.54%) |
Mkt cap ! $64.51M | |||
| Open | High | Low | Value | Volume |
| 57.0¢ | 58.5¢ | 56.5¢ | $3.293K | 5.744K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10000 | 57.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 58.5¢ | 8303 | 1 |
View Market Depth
| Last trade - 12.53pm 09/08/2024 (20 minute delay) ? |
| IIQ (ASX) Chart |